arrow
Z

Zhongmin Maxwell Wang

akeso biopharma
H指数:15
被引数:1,138

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial

可切除非小细胞肺癌的围手术期伊沃奈西单抗联合或不联合化疗:一项2期临床试验

2026-11-040
OAAI
Cadonilimab combined with lenvatinib and transarterial chemoembolization for non-metastatic unresectable hepatocellular carcinoma: a multicenter, open-label, phase 2 study

卡度尼利单抗联合仑伐替尼和肝动脉化疗栓塞术治疗非转移性不可切除肝细胞癌:一项多中心、开放标签、II期研究

2026-08-130
OA
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

Anti-PD-1抗体penpulimab联合化疗治疗复发或转移性鼻咽癌: 一项随机双盲3期研究

2026-04-080
OAAI
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

Ivonescimab 联合化疗与 tislelizumab 联合化疗作为晚期鳞状非小细胞肺癌的一线治疗(HARMONi-6):一项随机、双盲、Ⅲ期临床试验

2025-10-190
PRE
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial

Ivonescimab联合化疗治疗EGFR变异的非小细胞肺癌随机临床试验

2024-08-209
OA
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
2024-05-226
PRE